TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06293053: A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

Sponsor: Sanofi · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 20 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$439,632

Rescue Site Savings

+$293,088

Unlock Full NCT06293053 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06293053 Rescue Dossier →